These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32328844)

  • 1. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
    Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
    Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
    Wang F; Molina J; Satele D; Yin J; Lim VS; Adjei AA
    Invest New Drugs; 2019 Aug; 37(4):658-665. PubMed ID: 30382439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
    Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
    Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
    Spigel D; Jones S; Hainsworth J; Infante J; Greco FA; Thompson D; Doss H; Burris H
    Cancer Invest; 2011 May; 29(4):308-12. PubMed ID: 21469980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
    Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
    Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
    McRee AJ; Davies JM; Sanoff HG; Goldberg RM; Bernard S; Dees EC; Keller K; Ivanova A; O'Neil BH
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):117-23. PubMed ID: 24819684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
    Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
    Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
    Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
    Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
    Wood A; George S; Adra N; Chintala S; Damayanti N; Pili R
    Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
    Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
    Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
    Gerstner ER; Eichler AF; Plotkin SR; Drappatz J; Doyle CL; Xu L; Duda DG; Wen PY; Jain RK; Batchelor TT
    J Neurooncol; 2011 Jun; 103(2):325-32. PubMed ID: 20821342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
    Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
    Gupta P; Mulkey F; Hasserjian RP; Sanford BL; Vij R; Hurd DD; Odenike OM; Bloomfield CD; Owzar K; Stone RM; Larson RA;
    Invest New Drugs; 2013 Oct; 31(5):1311-20. PubMed ID: 23700288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
    Pedersen KS; Grierson PM; Picus J; Lockhart AC; Roth BJ; Liu J; Morton A; Chan E; Huffman J; Liang C; Wang-Gillam A; Tan B
    Invest New Drugs; 2021 Oct; 39(5):1298-1305. PubMed ID: 33738668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
    Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
    Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
    Sheng X; Yan X; Chi Z; Cui C; Si L; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Ding L; Mao L; Guo J
    EBioMedicine; 2020 May; 55():102755. PubMed ID: 32335374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
    Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.